Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSKRIP + Chemo in Recurrent/Persistent Cervical Cancer
NCT02446652Phase 3Withdrawn
- Sponsor
- Instituto Nacional de Cancerología
- Start
- Jan 2015
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydralazine, magnesium valproate in Cervical Cancer (CC), sponsored by Instituto Nacional de Cancerología. Planned start Jan 2015; status: withdrawn.
02
Drugs
hydralazinemagnesium valproate
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT02446652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446652.